GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (FRA:DV3R) » Definitions » Debt-to-Equity

Delcath Systems (FRA:DV3R) Debt-to-Equity : 0.65 (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Delcath Systems Debt-to-Equity?

Delcath Systems's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €9.34 Mil. Delcath Systems's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Delcath Systems's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €14.47 Mil. Delcath Systems's debt to equity for the quarter that ended in Dec. 2023 was 0.65.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Delcath Systems's Debt-to-Equity or its related term are showing as below:

FRA:DV3R' s Debt-to-Equity Range Over the Past 10 Years
Min: -8.96   Med: -0.14   Max: 1.34
Current: 0.65

During the past 13 years, the highest Debt-to-Equity Ratio of Delcath Systems was 1.34. The lowest was -8.96. And the median was -0.14.

FRA:DV3R's Debt-to-Equity is ranked worse than
79.83% of 709 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs FRA:DV3R: 0.65

Delcath Systems Debt-to-Equity Historical Data

The historical data trend for Delcath Systems's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Delcath Systems Debt-to-Equity Chart

Delcath Systems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.45 0.13 1.34 -2.71 0.65

Delcath Systems Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.71 -0.74 -40.79 0.40 0.65

Competitive Comparison of Delcath Systems's Debt-to-Equity

For the Medical Devices subindustry, Delcath Systems's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Delcath Systems's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Delcath Systems's Debt-to-Equity falls into.



Delcath Systems Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Delcath Systems's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Delcath Systems's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Delcath Systems  (FRA:DV3R) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Delcath Systems Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Delcath Systems's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Delcath Systems (FRA:DV3R) Business Description

Traded in Other Exchanges
Address
1633 Broadway, Suite 22C, New York, NY, USA, 10019
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Delcath Systems (FRA:DV3R) Headlines

No Headlines